8-K: Albertsons Reports Q4 Results, Boosts Dividend, Settles Opioid Claims

Albertsons Companies announced fourth quarter and full year fiscal 2025 results, a 13% increase in its quarterly dividend, and a framework to resolve opioid-related claims for approximately $774 million.

Summary

• Albertsons Companies reported fourth quarter and full year fiscal 2025 results ending February 28, 2026.
• The company announced a 13% increase in its quarterly cash dividend to $0.17 per common share.
• A settlement framework has been reached to resolve substantially all opioid-related claims for approximately $774 million, payable over nine years.
• Identical sales increased 0.7% in the fourth quarter and 2.0% for the full year.
• Digital sales saw a 16% increase in the fourth quarter and 21% for the full year.
• Net loss for the fourth quarter was $481 million, or $0.94 per share, impacted by the opioid settlement charge.
• Adjusted net income for the fourth quarter was $252 million, or $0.48 per share.
• Adjusted EBITDA for the fourth quarter was $903 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report; while the dividend increase and share repurchase authorization are positive, the net loss due to the opioid settlement and modest sales growth temper the overall sentiment.

Positives

• Identical sales increased 0.7% in Q4 FY2025 and 2.0% for the full year FY2025.
• Digital sales grew by 16% in Q4 FY2025 and 21% for the full year FY2025.
• Loyalty members increased by 12% to 51.2 million.
• The quarterly cash dividend was increased by 13% to $0.17 per common share.
• The remaining share repurchase authorization was increased to $2 billion.
• Adjusted EBITDA for Q4 FY2025 was $903.4 million, an increase from $855.1 million in Q4 FY2024.
• Adjusted net income per Class A common share for Q4 FY2025 was $0.48, up from $0.46 in Q4 FY2024.
• The company is committed to investing in its customer value proposition and advancing digital and loyalty programs.

Negatives

• The company reported a net loss of $481 million ($0.94 per share) for the fourth quarter of fiscal 2025, primarily due to a $600 million after-tax charge related to the Opioid Settlement Framework.
• Gross margin rate decreased to 27.2% in Q4 FY2025 from 27.4% in Q4 FY2024, mainly due to increased delivery and handling costs for digital sales.
• Selling and administrative expenses increased to 29.6% of net sales in Q4 FY2025 from 25.7% in Q4 FY2024.
• Interest expense increased to $141.1 million in Q4 FY2025 from $101.5 million in Q4 FY2024 due to higher average borrowings.
• Net income for the full year FY2025 was $217 million, a significant decrease from $959 million in FY2024.
• Adjusted EBITDA for the full year FY2025 was $3,902 million, a decrease from $4,005 million in FY2024.
• Identical sales growth was impacted by pharmacy headwinds related to the Inflation Reduction Act.
• The net debt ratio increased to 2.24 in FY2025 from 1.88 in FY2024.

Risks

• Pharmacy sales were impacted more than expected by pricing headwinds related to the Inflation Reduction Act (IRA).
• Increased delivery and handling costs related to the continued growth in digital sales are impacting gross margin.
• The company faces risks related to changes in macroeconomic conditions, consumer behavior, wage rates, and labor union negotiations.
• Geopolitical uncertainty and challenges in the competitive environment are potential risks.
• The company's ability to execute on its business strategies and attract/retain qualified associates is critical.
• Cyber incidents at the company or third parties could have operational and financial effects.
• The Opioid Settlement Framework is subject to contingencies, including sufficient participation levels.
• The fiscal 2026 outlook reflects an estimated 150 basis point headwind related to the Inflation Reduction Act's Medicare Drug Price Negotiation Program.

Future Outlook

For fiscal year 2026, Albertsons expects identical sales growth between 0.0% and 1.0%, Adjusted EBITDA in the range of $3.850 billion to $3.925 billion, and Adjusted net income per Class A common share between $2.22 and $2.32. Capital expenditures are projected to be between $2.0 billion and $2.2 billion. The outlook anticipates a 150 basis point headwind from the Inflation Reduction Act's Medicare Drug Price Negotiation Program.

Management Comments

• "Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong Adjusted EBITDA despite meaningful top-line pharmacy-related headwinds," said Susan Morris, CEO of Albertsons Companies.
• Morris continued, "Across the full year, we remained focused on building a stronger foundation for the future, including investing in our customer value proposition, advancing digital and loyalty, and strengthening the capabilities that support sustainable, longterm growth."
• "As we enter fiscal 2026, we are building on this foundation by scaling our productivity engine and positioning the company to deliver earnings growth, strong cash flow, and longterm shareholder returns."
• The increased dividend reflects the Company's confidence in its core business, the strength of the underlying free cash flow generation and its balanced approach to capital allocation over time.

Industry Context

StockSavvy.ai notes that Albertsons' results reflect ongoing trends in the grocery and pharmacy sector, including the growth of digital sales and the impact of regulatory changes like the Inflation Reduction Act on pharmacy margins. The significant opioid settlement highlights a broader legal and financial challenge faced by many retail pharmacy operators.

Comparison to Industry Standards

• The 0.7% identical sales growth in Q4 FY2025 is modest compared to some competitors in the grocery sector who have reported higher comparable store sales, particularly those with stronger private label penetration or more aggressive promotional strategies.
• The 16% digital sales growth is in line with or slightly below the higher end of growth rates seen by major retailers, indicating continued consumer adoption of online grocery shopping.
• The Adjusted EBITDA margin for Q4 FY2025 was approximately 4.46% ($903.4M / $20.3B), which is generally within the typical operating margin range for large supermarket chains, though can vary significantly based on product mix and operational efficiency.
• The dividend increase of 13% is a positive signal to shareholders, demonstrating confidence in free cash flow generation, though the yield may still be lower than some mature dividend-paying companies in the retail sector.

Legal Proceedings

• The company has reached a settlement framework to resolve substantially all opioid-related claims from participating states, political subdivisions, and Native American tribes for approximately $774 million over nine years.
• The company will continue to defend against any litigation not covered by the Opioid Settlement Framework.

Stakeholder Impact

• Shareholders: Benefit from a 13% increase in quarterly dividend and an increased share repurchase authorization, signaling confidence in financial health.
• Customers: May see continued investment in value proposition and digital offerings.
• Creditors: The opioid settlement and increased debt levels (reflected in higher interest expense and net debt ratio) could be a point of focus.
• Employees: Continued focus on strengthening capabilities and potential impacts from productivity initiatives.
• Participating Jurisdictions (States, Political Subdivisions, Tribes): Will receive payments totaling approximately $774 million over nine years as part of the opioid settlement.

Next Steps

• The company will continue to scale its productivity engine in fiscal 2026.
• Payments for the Opioid Settlement Framework are expected to begin in April 2026.
• The company will continue to invest in its customer value proposition, digital capabilities, and loyalty programs.
• The company will monitor the impact of the Inflation Reduction Act on pharmacy sales and margins.

Key Dates

Recommendation

The company reported a net loss due to a significant opioid settlement charge, although adjusted metrics and dividend increases are positive. Modest sales growth and ongoing headwinds from regulatory changes suggest a cautious outlook, warranting a 'hold' recommendation until clearer signs of sustained growth and profitability emerge post-settlement.

Keywords

Albertsons, SEC Filing, 8-K, Financial Results, Dividend, Opioid Settlement, Retail, Grocery